Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25533352 | 0.83 | SMN1; SMN2 (0.31) | SMN1; SMN2GAA | |
| SCHEMBL17713632 | 0.79 | HSD11B1 (0.40) | SMN1; SMN2ATMGSK3BDYRK1AHSD11B1 | |
| SCHEMBL25540021 | 0.79 | HRH3 (0.44) | SMN1; SMN2GSK3BDYRK1A | |
| SCHEMBL2657574 | 0.78 | NLRP3 (0.34) | SMN1; SMN2ATMGSK3BDYRK1AHSD11B1 | |
| SCHEMBL19383726 | 0.77 | SMN1; SMN2 (0.41) | SMN1; SMN2HSD11B1LMNA | |
| SCHEMBL14855022 | 0.76 | HSD11B1 (0.32) | SMN1; SMN2ATMGSK3BDYRK1AHSD11B1 | |
| SCHEMBL16133075 | 0.76 | ABL1 (0.40) | SMN1; SMN2ATMGSK3BDYRK1AHSD11B1 | |
| SCHEMBL25530319 | 0.76 | ATM (0.36) | SMN1; SMN2ATMGSK3BDYRK1AGAA | |
| SCHEMBL10205107 | 0.75 | SMN1; SMN2 (0.53) | SMN1; SMN2ATMGAA | |
| SCHEMBL22254760 | 0.74 | TSHR (0.43) | SMN1; SMN2GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | SMN1; SMN2 4817/4885ATM 4286/4885GSK3B 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.